Trial · NCT06632405
A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC
NCT06632405, Phase 2, Not yet recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC. Trials, record NCT06632405. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06632405
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC
- NCT number
- NCT06632405
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Conditions
- Breast Cancer
- Interventions
- Camrelizumab, Nab paclitaxel, Levocetirizine Hydrochloride
- First posted
- 2024-10-09
- Last updated
- 2025-03-26
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall response rate (ORR) | from the first drug administration up to the first occurrence of progression or death （up to 36 weeks） | The propotion of subjects with CR or PR. |
| Secondary | Adverse events/Serious adverse events | from the first drug administration to within 90 days for the last dose | Adverse events/Serious adverse events |
| Secondary | Disease Control Rate (DCR) | from the first drug administration up to the first occurrence of progression or death （up to 36 weeks） | The propotion of subjects with CR, PR, or SD. |
| Secondary | Clinical benefit rate (CBR) | propotion of subjects with CR, PR, or SD for >=6 months （up to 36 weeks） | The propotion of subjects with CR, PR, or SD for \>=6 months during the study |
| Secondary | Duration of response (DoR) | from the first drug administration up to the first occurrence of progression or death （up to 36 weeks） | The time from randomization to disease progression or death for patients who achieve complete or partial alleviation |
| Secondary | Time to response (TTR) | from the first drug administration up to the first occurrence of progression （up to 36 weeks） | Time from date of first dose to date of first occurrence of response |
| Secondary | Progression-Free-Survival (PFS) | from the first drug administration up to the first occurrence of progression or death （up to 36 weeks） | from the first drug administration up to the first occurrence of progression or death (up to 24 months) |
| Secondary | Overall survival (OS) | 12 months after the first drug administration | 12 months after the first drug administration |
| Secondary | Biomarkers | pre-treatment, up to 24 months | Compare the change of biomarkers from urine, blood or tissues, such as the carcinoembryonic antigen (ug/L), before or after the treatments. |
| Secondary | Biomarkers | pre-treatment, up to 24 months | Compare the change of biomarkers from urine, blood or tissues, such as the CA125/199/153(u/ml), before or after the treatments. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06632405
GET https://conductscience.org/api/trials/v1/NCT06632405/registered